Exenatide versus glimepiride monotherapy in management of patients with type 2 diabetes
(2013) Exenatide versus glimepiride monotherapy in management of patients with type 2 diabetes, no. 42.
Diabetes mellitus is a chronic condition associated with defective secretion of insulin or a defect in the action of insulin as both lead to chronic hyperglycaemia resulting in a number of health related complications. Exenatide and glimepiride are two important drugs in treatment of type2 diabetes. These two drugs are superior drugs in their respective classification with minimal side effects which can be managed with dose adjustments. Aims The main aim of this research is to compare the effect of the exenatide with glimepiride when used as monotherapy to control blood glucose levels (measured by HbA1c levels) in patients with type 2 diabetes. This will be the primary outcome measure of the study. The secondary outcome measures will be fasting plasma levels, postprandial plasma levels, serum lipid concentrations, body mass index and other side effects such as hypoglycaemia, nausea and gastrointestinal disturbances. Methods This is a quantitative research proposal which will be conducted in a number of centres through out Edinburgh (Scotland). This study will be a double blind, randomised control clinical trial, and it will be a parallel group study design which will be completed in 26 weeks. Power calculation to determine the sample size will be carried out for appropriate selection of patients. Ethical approval will be requested from Queen Margaret University ethics committee and if required will be submitted to NHS Edinburgh ethics. This study will be randomised and patients will receive 1:1 of ratio exenatide and glimepiride. Laboratory investigation will be done for 26 weeks at regular intervals. Primary and secondary outcomes will be measured. Conclusion There are various treatment options available for patients with type 2 diabetes along with diet and life style modifications. Exenatide is of the novel promising drug for patients with type 2 diabetes with good efficacy in reducing the blood glucose levels along with reduction weight.